10 Best Performing Growth Stocks in 2025

4. TG Therapeutics, Inc. (NASDAQ:TGTX)

YTD-Performance: 26.30%

Number of Hedge Fund Holders: 36

TG Therapeutics, Inc. (NASDAQ:TGTX) is a commercial-stage biopharmaceutical company that focuses on developing and commercializing treatments for B-cell diseases. The FDA has approved the company’s BRIUMVI for treating relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

On March 4th, Analyst Edward White from H.C. Wainwright reiterated a Buy rating on the stock with a price target of $55. The analyst highlighted that he reiterated the rating due to the strong financial results and promising future of TG Therapeutics, Inc. (NASDAQ:TGTX). The company’s fourth quarter 2024 results surpassed expectations, with GAAP and non-GAAP EPS exceeding estimates, driven by strong sales of Briumvi. The company also grew its revenue by 146% year-over-year to reach $108.18 million. Analyst White is also encouraged by the optimistic guidance for 2025, which projects substantial growth in revenue and earnings. TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the best-performing growth stocks in 2025 with a year-to-date gain of 26.3%.

ClearBridge Small Cap Growth Strategy stated the following regarding TG Therapeutics, Inc. (NASDAQ:TGTX) in its Q4 2024 investor letter:

“2024 proved a particularly active year for new idea generation: we added 23 new investments while exiting 29 due to a variety of considerations, including acquisitions, market capitalization constraints, and our assessment of forward return potential. While many of the new investments we made during the year are of relatively modest size, we will continue to build these positions over time provided company execution and end market prospects remain intact. In the fourth quarter we initiated five new investments: Oscar Health,TG Therapeutics, Inc. (NASDAQ:TGTX), Clearwater Analytics, Fluor and Modine.

TG Therapeutics is a commercial stage biotechnology company focused on multiple sclerosis (MS), a significant chronic disease end market. Its lead product, Briumvi, has the potential to grow its market share significantly within the largest drug class in the $8 billion MS market.”